BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 27908619)

  • 1. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
    Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
    Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
    Mlak R; Krawczyk P; Homa-Mlak I; Powrózek T; Ciesielka M; Kozioł P; Milanowski J; Małecka-Massalska T
    Pathol Oncol Res; 2019 Jul; 25(3):1035-1045. PubMed ID: 30066234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
    Li Y; Huang XE; Jin GF; Shen HB; Xu L
    Asian Pac J Cancer Prev; 2011; 12(3):739-42. PubMed ID: 21627375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
    Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
    PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
    Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
    Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
    Ryu JS; Shin ES; Nam HS; Yi HG; Cho JH; Kim CS; Kim HJ; Lee JE
    J Thorac Oncol; 2011 Aug; 6(8):1320-9. PubMed ID: 21642870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between polymorphisms of BAG-1 and XPD and chemotherapy sensitivity in advanced non-small-cell lung cancer patients treated with vinorelbine combined cisplatin regimen.
    Li P; Wang YD; Cheng J; Chen JC; Ha MW
    Tumour Biol; 2015 Dec; 36(12):9465-73. PubMed ID: 26124006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
    Rosell R; Felip E; Taron M; Majo J; Mendez P; Sanchez-Ronco M; Queralt C; Sanchez JJ; Maestre J
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4215s-4219s. PubMed ID: 15217961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
    Cheng H; Qin Q; Sun X; Li F; Sun N; Cheng L; Lu Z; Chen B
    Technol Cancer Res Treat; 2013 Oct; 12(5):473-82. PubMed ID: 23617284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
    Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
    Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
    Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
    Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R; Taron M; Camps C; López-Vivanco G
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Liu L; Yuan P; Wu C; Zhang X; Wang F; Guo H; Zhong R; Xu Y; Wu J; Yu D; Wu T; Zhang X; Nie S; Miao X; Lin D
    Lung Cancer; 2011 Jul; 73(1):110-5. PubMed ID: 21129812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
    Nie X; Cheng G; Ai B; Zhang S
    Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
    Zhou M; Ding YJ; Feng Y; Zhang QR; Xiang Y; Wan HY
    Genet Mol Res; 2014 Apr; 13(2):3310-8. PubMed ID: 24841663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer.
    Isla D; Sarries C; Rosell R; Alonso G; Domine M; Taron M; Lopez-Vivanco G; Camps C; Botia M; Nuñez L; Sanchez-Ronco M; Sanchez JJ; Lopez-Brea M; Barneto I; Paredes A; Medina B; Artal A; Lianes P
    Ann Oncol; 2004 Aug; 15(8):1194-203. PubMed ID: 15277258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
    Li XD; Han JC; Zhang YJ; Li HB; Wu XY
    Asian Pac J Cancer Prev; 2013; 14(1):145-8. PubMed ID: 23534713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.